Clostridium difficile infection is one of the most common healthcare-associated infections in adults in the United States. Older Americans are especially vulnerable to CDI, 2 and this infection has ...

Singulex’s Clarity C. diff toxin A/B assay, a rapid C. diff toxin test, has made its commercial debut, the company announced. “The Clarity toxin A/B assay offers a new approach to testing for C. diff ...

The largest study of its kind has shown the most effective test for the diagnosis of Clostridium difficile (C-Diff), a bacterial infection which causes 15,000-20,000 deaths a year in hospitals in the ...

Tests for the Clostridium difficile infection are missing up to 20% of cases and falsely diagnosing thousands of others, researchers have said. A study by St George's, University of London, and St ...

Clinical findings shed more light on toxins produced by C. diff A team from Nashville, Tenn.-based VanderbiltUniversityMedicalCenter has teased out new secrets from Clostridium difficile, the ...

Dear Dr. Roach: I had two previous episodes of C. diff and was treated with vancomycin. My stool tests the first time were negative. Recently, I got the same symptoms, and the doctor did a stool test ...

A new study, led by researchers from the University of California, Irvine (UCI), uncovers the long-sought-after, three-dimensional structure of a toxin primarily responsible for devastating ...

A new article details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff -- a virulent health care-associated infection that causes ...

A novel combination of multiple advanced molecular imaging techniques has led to the discovery of two molecular structures, which could provide a therapeutic target for C. diff infections. “The most ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

NEW YORK, January 2, 2020 -- A newly published paper in PNAS details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff-- a virulent ...